Charlebois A, Deslauriers N, Maduro L, Boulianne M
Microorganisms. 2025; 13(1).
PMID: 39858888
PMC: 11767711.
DOI: 10.3390/microorganisms13010120.
van Kessel J, Camilli A
J Bacteriol. 2024; 206(11):e0024824.
PMID: 39405459
PMC: 11580405.
DOI: 10.1128/jb.00248-24.
Hauke C, Taylor R
PLoS One. 2017; 12(4):e0175170.
PMID: 28384206
PMC: 5383245.
DOI: 10.1371/journal.pone.0175170.
Maldarelli G, Matz H, Gao S, Chen K, Hamza T, Yfantis H
J Vaccines Vaccin. 2016; 7(3).
PMID: 27375958
PMC: 4927082.
DOI: 10.4172/2157-7560.1000321.
Yoon M, Min K, Lee K, Yoon Y, Kim Y, Oh Y
Nat Commun. 2016; 7:11606.
PMID: 27173141
PMC: 5482719.
DOI: 10.1038/ncomms11606.
Immunizing adult female mice with a TcpA-A2-CTB chimera provides a high level of protection for their pups in the infant mouse model of cholera.
Price G, Holmes R
PLoS Negl Trop Dis. 2014; 8(12):e3356.
PMID: 25474636
PMC: 4256283.
DOI: 10.1371/journal.pntd.0003356.
Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile.
Maldarelli G, De Masi L, von Rosenvinge E, Carter M, Donnenberg M
Pathog Dis. 2014; 71(3):302-14.
PMID: 24550179
PMC: 4130776.
DOI: 10.1111/2049-632X.12137.
Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.
Leitner D, Feichter S, Schild-Prufert K, Rechberger G, Reidl J, Schild S
Infect Immun. 2013; 81(7):2379-93.
PMID: 23630951
PMC: 3697601.
DOI: 10.1128/IAI.01382-12.
Structure of the Vibrio cholerae Type IVb Pilus and stability comparison with the Neisseria gonorrhoeae type IVa pilus.
Li J, Egelman E, Craig L
J Mol Biol. 2012; 418(1-2):47-64.
PMID: 22361030
PMC: 3389824.
DOI: 10.1016/j.jmb.2012.02.017.
Step-wise loss of bacterial flagellar torsion confers progressive phagocytic evasion.
Lovewell R, Collins R, Acker J, OToole G, Wargo M, Berwin B
PLoS Pathog. 2011; 7(9):e1002253.
PMID: 21949654
PMC: 3174259.
DOI: 10.1371/journal.ppat.1002253.
Vibrio cholerae: lessons for mucosal vaccine design.
Bishop A, Camilli A
Expert Rev Vaccines. 2010; 10(1):79-94.
PMID: 21162623
PMC: 3036168.
DOI: 10.1586/erv.10.150.
Characterization of a novel protective monoclonal antibody that recognizes an epitope common to Vibrio cholerae Ogawa and Inaba serotypes.
Dharmasena M, Krebs S, Taylor R
Microbiology (Reading). 2009; 155(Pt 7):2353-2364.
PMID: 19389772
PMC: 2888117.
DOI: 10.1099/mic.0.025726-0.
Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum).
Sharma M, Singh N, Jani D, Sisodia R, Thungapathra M, Gautam J
Plant Cell Rep. 2007; 27(2):307-18.
PMID: 17962948
DOI: 10.1007/s00299-007-0464-y.
Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.
Rollenhagen J, Kalsy A, Cerda F, John M, Harris J, LaRocque R
Infect Immun. 2006; 74(10):5834-9.
PMID: 16988262
PMC: 1594919.
DOI: 10.1128/IAI.00438-06.
TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups.
Kirn T, Taylor R
Infect Immun. 2005; 73(8):4461-70.
PMID: 16040956
PMC: 1201224.
DOI: 10.1128/IAI.73.8.4461-4470.2005.
A Vibrio cholerae classical TcpA amino acid sequence induces protective antibody that binds an area hypothesized to be important for toxin-coregulated pilus structure.
Taylor R, Kirn T, Meeks M, Wade T, Wade W
Infect Immun. 2004; 72(10):6050-60.
PMID: 15385509
PMC: 517590.
DOI: 10.1128/IAI.72.10.6050-6060.2004.
The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139.
Asaduzzaman M, Ryan E, John M, Hang L, Khan A, Faruque A
Infect Immun. 2004; 72(8):4448-54.
PMID: 15271902
PMC: 470637.
DOI: 10.1128/IAI.72.8.4448-4454.2004.
Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies.
Meeks M, Saksena R, Ma X, Wade T, Taylor R, Kovac P
Infect Immun. 2004; 72(7):4090-101.
PMID: 15213154
PMC: 427411.
DOI: 10.1128/IAI.72.7.4090-4101.2004.
Detection of antibodies to toxin-coregulated pili in sera from cholera patients.
Attridge S, Wallerstrom G, Qadri F, Svennerholm A
Infect Immun. 2004; 72(3):1824-7.
PMID: 14977996
PMC: 356006.
DOI: 10.1128/IAI.72.3.1824-1827.2004.
Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae.
Hang L, John M, Asaduzzaman M, Bridges E, Vanderspurt C, Kirn T
Proc Natl Acad Sci U S A. 2003; 100(14):8508-13.
PMID: 12826608
PMC: 166259.
DOI: 10.1073/pnas.1431769100.